- Reported transaction lines
- 1
- Buy lines
- 0
- Sell lines
- 1
Filing activity by month
Original filing lines in up to 12 months with activity.
- 2026-111
Frequently disclosed stocks
Disclosure history
| Reporting investor | Security | Activity | Transaction / period | Filed | Reported amount | Source |
|---|---|---|---|---|---|---|
| Burns John Thomas CFO · SELLAS Life Sciences Group, Inc. | SLS SELLAS Life Sciences Group, Inc. | SellFiling detailsSEC transaction code S Common Stock · Direct ownership · Reported balance after transaction: 558893 · SEC code covers open-market or private transactions · Represents shares sold to satisfy the Reporting Person's tax withholding obligation in connection with the performance based vesting of certain previously granted restricted stock units upon meeting the primary endpoint in the Issuer's Phase 3 REGAL study. These sales are mandated as part of the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. | 2026-11-18 | 2026-11-20 | ≈ $73,470.92 3,831 shares/units | SEC 4 |
Counts describe original filing lines in BriefStock’s coverage. Later amendments can correct or supplement them. Check the original filing for ownership and transaction details.